3050 Spruce Street, St. Louis, MO 63103 USA
Tel: (800) 521-8956 (314) 771-5765 Fax: (800) 325-5052 (314) 771-5757
email: techservice@sial.com sigma-aldrich.com

Product Information

Anti-VRK1 (C-terminal)

produced in rabbit, affinity isolated antibody

Product Number V1890

Product Description

Anti-VRK1 (C-terminal) is developed in rabbit using as the immunogen a synthetic peptide corresponding to a sequence at the C-terminal of human VRK1 (GenelD: 7443), conjugated to KLH. The corresponding sequence is not conserved in mouse and rat VRK1. The antibody is affinity-purified using the immunizing peptide immobilized on agarose.

Anti-VRK1 (C-terminal) specifically recognizes human VRK1. The antibody may be used in various immunochemical techniques including immunoblotting (~45 kDa). Detection of the VRK1 band by immunoblotting is specifically inhibited by the VRK1 immunizing peptide.

The vaccinia related kinases (VRKs) comprise a new family of ubiquitously expressed Ser/Thr protein kinases with homology to the vaccinia virus B kinase. 1,2 The VRK orthologues encoded by c. elegans and drosophila melanogaster play an essential role in cell division. Mammalian genome encodes three VRK proteins, VRK1-3, that differ in their subcellular distribution and enzymatic activity.2 VRK1 has been reported to be localized to the nucleus and is enzymatically active. VRK1 is able to phosphorylate and regulate the activity of transcription factors implicated in stress-related cellular responses, including c-Jun, ATF2, and the BAF protein required for nuclear envelope assembly. 3-6 Human VRK1 has been shown to phosphorylate p53 at Thr¹⁸ resulting in its stabilization by preventing the p53-Hdm2 interaction, and activation of p53-dependent gene transcription.³ In turn, the stable accumulation of p53 induces a proteolytic degradation of VRK1 by an autoregulatory mechanism, via the endosome-lysosome pathway. PI3K interacts and phosphorylates VRK1 in a signaling pathway that induces Golgi fragmentation.7 Inactivation of VRK1 causes a block in cell cycle progression, consistent with its role in highly proliferating cells, during development.8

Reagent

Supplied as a solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Antibody concentration: ~1.0 mg/mL

Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

Store at –20 °C. For continuous use, the product may be stored at 2–8 °C for up to one month. For extended storage, freeze in working aliquots at –20 °C. Repeated freezing and thawing, or storage in "frost-free" freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.

Product Profile

 $\underline{Immunoblotting}\hbox{: a working antibody concentration of }1.0\mbox{-}2.0~\mu g/mL \mbox{ is recommended using a MCF7 cell } lysate.$

<u>Note</u>: In order to obtain best results in various techniques and preparations, it is recommended to determine optimal working dilutions by titration.

References

- 1. Nezu, J. et al., Genomics, 45, 327-331 (1997).
- Nichols, R.J., and Traktman, P., J. Biol. Chem., 279, 7934-7946 (2004).
- 3. Vega, F.M. et al., *Mol. Cell. Biol.*, **24**, 10366-10380 (2004).
- Sevilla, A. et al., J. Biol. Chem., 279, 27458-27465 (2004).
- 5. Sevilla, A. et al., Oncogene, 23, 8950-8958 (2004).
- Nichols, R.J. et al., Mol. Biol. Cell, 17, 2451-2464 (2006).
- 7. Lopez-Sanchez, I. et al., *Mol. Cell. Biol.*, **29**, 1189-1201 (2009).
- Valbuena, A. et al., PLoS One, 3, e1642 (2008).

VS,ER,TD,KAA,PHC,MAM 04/19-1